Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

6.385 -0.225 (-3.40%)

Delayed Quote Updated: 11:30 AM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs ↗

July 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 22, 2021

Gainers Xenetic Biosciences (NASDAQ:XBIO...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million

July 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration

June 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 08, 2021

Gainers Aethlon Medical (NASDAQ:AEMD) sto...

Via Benzinga

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

May 26, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

May 05, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 03, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant

May 03, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

65 Biggest Movers From Yesterday ↗

April 30, 2021

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs. Takung Art Co., Ltd. (...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 29, 2021

Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at...

Via Benzinga

54 Stocks Moving In Thursday's Mid-Day Session ↗

April 29, 2021

Gainers Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39. Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment...

Via Benzinga

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report First Quarter 2021 Financial Results

April 28, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.